Comparison of analysis techniques for the lattice Boltzmann method

A. Caiazzo,M. Junk,Martin Rheinländer

DOI: https://doi.org/10.1016/j.camwa.2009.02.011

2009-09-01

Abstract:

What problem does this paper attempt to address?

Ghrelin and the cardiovascular system

Takeshi Tokudome,Ichiro Kishimoto,Mikiya Miyazato,Kenj Kangawa

DOI: https://doi.org/10.1159/000360593

Abstract:Ghrelin is a peptide that was originally isolated from the stomach. It exerts potent growth hormone (GH)-releasing and orexigenic activities. Several studies have highlighted the therapeutic benefits of ghrelin for the treatment of cardiovascular disease. In animal models of chronic heart failure, the administration of ghrelin improved cardiac function and remodeling; these findings were replicated in human patients with heart failure. Moreover, in an animal study, ghrelin administration effectively reduced pulmonary hypertension induced by chronic hypoxia. In addition, repeated administration of ghrelin to cachectic patients with chronic obstructive pulmonary disease had positive effects on overall body function, including muscle wasting, functional capacity and sympathetic activity. The administration of ghrelin early after myocardial infarction (MI) reduced fatal arrhythmia and related mortality. In ghrelin-deficient mice, both exogenous and endogenous ghrelin were protective against fatal arrhythmia and promoted remodeling after MI. Although the mechanisms underlying the effects of ghrelin on the cardiovascular system remain unclear, there are indications that its beneficial effects are mediated through both direct physiological actions, including increased GH levels, improved energy balance and direct actions on cardiovascular cells, and regulation of autonomic nervous system activity. Therefore, ghrelin is a promising novel therapeutic agent for cardiovascular disease.
Isolation in Portugal of West Nile virus from Anopheles maculipennis mosquitoes.

A. Filipe

Acta Virologica

Abstract:
Ghrelin As a Treatment for Cardiovascular Diseases

Yuanjie Mao,Takeshi Tokudome,Ichiro Kishimoto

DOI: https://doi.org/10.1161/hypertensionaha.114.03726

IF: 9.8968

2014-01-01

Hypertension

Abstract:G hrelin, a growth hormone-releasing peptide that was first discovered in the stomach of rats in 1999, is an endogenous ligand of growth hormone secretagogue receptors (GHSRs). 1 Through binding to its receptors in the brain, ghrelin was initially shown to strongly stimulate the release of growth hormone and promote food intake. 2 Subsequent studies revealed that GHSRs are expressed ubiquitously in many organs and tissues, and ghrelin functionally participates in the regulation of diverse processes including appetite control, energy balance, body weight maintenance, glucose and fat metabolism, cell proliferation, and apoptosis, as well as the modulation of gastrointestinal, cardiovascular, pulmonary, and immune functions. 3,4The primary receptor of ghrelin is currently thought to be GHSR1a; however, other unidentified receptors might exist. 5,6The high expression of GHSR1a in the heart and large vessels provides evidence of its cardiac activity, 7 indicating ghrelin is a promising new therapeutic agent for cardiovascular diseases.In this review, we discuss some of the characteristic features of ghrelin treatment and its possible therapeutic roles in animals and patients afflicted with common cardiovascular diseases.
The Treatment of Ghrelin on Cardiac Cachexia in Congestive Heart Failure

XU Jian-ping,LIU Yang,HE Ge,YANG Bao-yan,YANG Bao-wei,TANG Chao-shu

2012-01-01

Abstract:Ghrelin can promote growth-hormone releasing,vascular relaxing and lower blood pressure to improve heart performance.Ghrelin can also increase appetite,gain body weight and involve in regulating the metabolism of glucose and fat as well.Ghrelin can improve the function of blood vessel endothelium,inhibit inflammatory cell factor and myocardial hypertrophy so as to prevent myocardial remodeling.As an endogenous protective factor against myocardial damage,Ghrelin,by various mechanisms,can improve cardiac function in heart failure and cause positive energy balance,resulting in attenuating the development of cardiac cachexia in chronic heart failure.With its beneficial effect in against metabolic remodeling,Ghrelin may be a potential therapeutic approach to cachectic heart failure.As a monitoring index,Ghrelin may be used in evaluating the severity of heart failure and prognosis of the patients with heart failure.
Effect of Ghrelin on Energy Metabolism in Chronic Heart Failure

Chaoshu Tang

2011-01-01

Abstract:Ghrelin stimulates appetite and weight gain,inducing obesity through a growth hormone-independent mechanism.It is involved in glucose and fat metabolism.Ghrelin could improve cardiac function and disturbed energy metabolism through inhibiting the production of inflammatory factors and myocardial remodeling in cachectic patients with chronic heart failure.Therefore,ghrelin plays an important role in maintaining homeostasis of myocardial energy metabolism in cachectic patients with chronic heart failure.With the beneficial effects of ghrelin on reversing myocardial remodeling,it may be a new therapeutic strategy for cachectic patients with end-stage heart failure.As a monitoring index,ghrelin might aid in the evaluation of the severity of the disease and patient prognosis.
Ghrelin Protects Heart Against ERS-induced Injury and Apoptosis by Activating AMP-activated Protein Kinase

Gai-Gai Zhang,Huai-Qiu Cai,Yan-Hui Li,Yu-Bin Sui,Jin-Sheng Zhang,Jin-Rui Chang,Ming Ning,Yang Wu,Chao-Shu Tang,Yong-Fen Qi,Xin-Hua Yin

DOI: https://doi.org/10.1016/j.peptides.2013.08.015

IF: 3.867

2013-01-01

Peptides

Abstract:Ghrelin, the endogenous ligand of growth hormone secretagogue receptor (GHS-R), is a cardioprotective peptide. In our previous work, we have revealed that ghrelin could protect heart against ischemia/reperfusion (I/R) injury by inhibiting endoplasmic reticulum stress (ERS), which contributes to many heart diseases. In current study, using both in vivo and in vitro models, we investigated how ghrelin inhibits myocardial ERS. In the in vivo rat heart injury model induced by isoproterenol (ISO), we found that exogenous ghrelin could alleviate heart dysfunction, reduce myocardial injury and apoptosis and inhibit the excessive myocardial ERS induced by ISO. More importantly, the activation of AMP-activated protein kinase (AMPK) was observed. To explore the role of AMPK activation in ERS inhibition by ghrelin, we set up two in vitro ERS models by exposing cultured rat cardiomyocytes to tunicamycin(Tm) or dithiothreitol (DTT). In both models, compared with Tm or DTT treatment alone, pre-incubation cardiomyocytes with ghrelin significantly activated AMPK, reversed the upregulation of the ERS markers, C/EBP-homologous protein (CHOP) and cleaved caspase-12, and reduced apoptosis of cardiomyocytes. Further, we found that the ERS inhibitory and anti-apoptotic actions induced by ghrelin were blocked by an AMPK inhibitor. To investigate how ghrelin activates AMPK, selective antagonist of GHS-R1a and inhibitor of Ca(2+)/Calmodulin-dependent protein kinase kinase (CaMKK) were added, respectively, before ghrelin pre-incubation, and we found that AMPK activation was prevented and the ERS inhibitory and anti-apoptotic actions of ghrelin were blocked. In conclusion, ghrelin could protect heart against ERS-induced injury and apoptosis, at least partially through a GHS-R1a/CaMKK/AMPK pathway.
Ghrelin inhibited pressure overload-induced cardiac hypertrophy by promoting autophagy via CaMKK/AMPK signaling pathway

Weiwei Lu,Huaiqiu Cai,Yao Chen,Xiang Liao,Linshuang Zhang,Tongtong Ma,Hong Sun,Yongfen Qi

DOI: https://doi.org/10.1016/j.peptides.2020.170446

IF: 3.867

2021-01-01

Peptides

Abstract:Ghrelin, a novel gut hormone, has been shown to exert protective effects on cardiac dysfunction and remodeling. However, the underlying mechanisms of its protective effects remain unclear. Here, we investigated the effects of ghrelin on cardiac hypertrophy and explored the mechanisms involved. Ghrelin (30 mu g.kg(-1). day(-1)) was systemically administered to rats with cardiac hypertrophy induced by abdominal aortic constriction (AAC) by a mini-osmotic pump the next day after surgery continuously for 4 weeks. The AAC treated rats without ghrelin infusion showed decreased ghrelin content and expression of its receptors in the hearts. Exogenous ghrelin greatly attenuated cardiac hypertrophy as shown by heart weight to tibial length (HW/TL), hemodynamics, echocardiography, histological analyses, and expression of hypertrophic markers induced by AAC. This corresponded with decreased cardiac fibrosis and inflammation in the hearts of AAC rats treated with ghrelin. Moreover, ghrelin significantly increased the myocardial expression of autophagy markers, which was further confirmed in cultured cardiomyocytes. Concurrently, cardiomyocyte apoptosis in vivo and in vitro was ameliorated by ghrelin, which was reversed by inhibition of autophagy. The enhancement of autophagy and inhibition of apoptosis by ghrelin were eliminated on pretreatment with compound C, an AMP-activated protein kinase (AMPK) inhibitor. Furthermore, inhibition of Ca2+/Calmodulin-dependent protein kinase kinase (CaMKK), an upstream kinase of AMPK, made ghrelin fail to activate AMPK and simultaneously reversed ghrelin's promotion of autophagy. In conclusion, ghrelin could exert its cardioprotective effects on cardiac hypertrophy by promoting autophagy, possibly via CaMKK/AMPK signaling pathway.
Endogenous Ghrelin Attenuates Pressure Overload-Induced Cardiac Hypertrophy Via A Cholinergic Anti-Inflammatory Pathway

Yuanjie Mao,Takeshi Tokudome,Ichiro Kishimoto,Kentaro Otani,Hirohito Nishimura,Osamu Yamaguchi,Kinya Otsu,Mikiya Miyazato,Kenji Kangawa

DOI: https://doi.org/10.1161/hypertensionaha.114.04864

IF: 9.8968

2015-01-01

Hypertension

Abstract:Cardiac hypertrophy, which is commonly caused by hypertension, is a major risk factor for heart failure and sudden death. Endogenous ghrelin has been shown to exert a beneficial effect on cardiac dysfunction and postinfarction remodeling via modulation of the autonomic nervous system. However, ghrelin’s ability to attenuate cardiac hypertrophy and its potential mechanism of action are unknown. In this study, cardiac hypertrophy was induced by transverse aortic constriction in ghrelin knockout mice and their wild-type littermates. After 12 weeks, the ghrelin knockout mice showed significantly increased cardiac hypertrophy compared with wild-type mice, as evidenced by their significantly greater heart weight/tibial length ratios (9.2±1.9 versus 7.9±0.8 mg/mm), left ventricular anterior wall thickness (1.3±0.2 versus 1.0±0.2 mm), and posterior wall thickness (1.1±0.3 versus 0.9±0.1 mm). Furthermore, compared with wild-type mice, ghrelin knockout mice showed suppression of the cholinergic anti-inflammatory pathway, as indicated by reduced parasympathetic nerve activity and higher plasma interleukin-1β and interleukin-6 levels. The administration of either nicotine or ghrelin activated the cholinergic anti-inflammatory pathway and attenuated cardiac hypertrophy in ghrelin knockout mice. In conclusion, our results show that endogenous ghrelin plays a crucial role in the progression of pressure overload–induced cardiac hypertrophy via a mechanism that involves the activation of the cholinergic anti-inflammatory pathway.
Recent Advances in the Biological Function of Ghrelin

CHEN Bin,WU Tian-xing

DOI: https://doi.org/10.3969/j.issn.0258-7033.2005.10.029

2005-01-01

Abstract:Ghrelin,a novel 28-amino-acid peptide purified from rat and human stomachs,is the endogenous ligand for the growth hormone secretagogue receptor(GHS-R) and has strong growth hormone-releasing activity.Ghrelin displays the physiological effects through the binding with GHS-R in the hypothalamus and pituitary.Functionally,ghrelin not only increases the GH release,but also is related to body growth,appetite,food intake,energy metabolism,and gastric acid secretion.This review summarized recent developments on structure,distribution,biological functions of ghrelin as well as its potential application in animal husbandry.
Ghrelin and Blood Pressure Regulation

Yuanjie Mao,Takeshi Tokudome,Ichiro Kishimoto

DOI: https://doi.org/10.1007/s11906-015-0622-5

2016-01-01

Current Hypertension Reports

Abstract:Ghrelin is a growth hormone-releasing polypeptide that was first isolated from the rat stomach in 1999. High expression of growth hormone secretagogue receptor, the ghrelin receptor, in the heart, kidney, and blood vessels provides evidence of ghrelin activity in blood pressure regulation. Circulating ghrelin concentrations are reported to be inversely correlated with blood pressure, and the acute and chronic effects of ghrelin in decreasing blood pressure have been reported in animals with normal blood pressure, healthy individuals, animals and patients with heart failure, and animals with hypertension. The mechanism by which ghrelin regulates blood pressure appears to be related to modulation of the autonomic nervous system, direct vasodilatory activities, and kidney diuresis. Thus, modulation of the signaling pathway through ghrelin may provide a novel concept for treating hypertension. In this review, we discuss the current evidence and potential mechanisms of ghrelin activity in blood pressure regulation.
Protective Effects of Ghrelin on Ischemia/reperfusion Injury in the Isolated Rat Heart.

L Chang,YS Ren,XH Liu,WG Li,JH Yang,B Geng,NL Weintraub,CS Tang

DOI: https://doi.org/10.1097/00005344-200402000-00001

IF: 3.271

2004-01-01

Journal of Cardiovascular Pharmacology

Abstract:Ghrelin, an endogenous ligand of the growth hormone secretagogue receptor, has been reported to have beneficial effects on cardiac function. The authors used the Langendorff model of ischemia/reperfusion (I/R) injury in isolated rat heart to determine whether ghrelin exerts direct cardioprotective effects. Also, the capacity of ghrelin to bind to sarcolemmal membrane fractions before and after ischemia and reperfusion was examined. Compared with vehicle administration, administration of ghrelin (100-10,000 pM) during the reperfusion period resulted in improvement in coronary flow, heart rate, left ventricular systolic pressure, and left ventricular end-diastolic pressure. Ghrelin also enhanced the rates of left ventricular contraction and relaxation after ischemia following reperfusion. Administration of ghrelin during reperfusion reduced myocardial release of lactate dehydrogenase and myoglobin, indicating protection against cardiomyocyte injury. In addition, ghrelin attenuated the depletion of myocardial ATP resulting from ischemia and reperfusion. A receptor-binding assay demonstrated that maximum binding capacity of ghrelin to sarcolemmal membranes was significantly increased after ischemia and was further increased after I/R. However, Scatchard analysis showed that the affinity of ghrelin for its receptor was not altered. The authors have concluded that administration of ghrelin during reperfusion protects against myocardial I/R injury. The cardioprotective effects are independent of growth hormone release and likely involve binding to cardiovascular receptors, a process that is upregulated during I/R.
Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Beta/Beta-Catenin Signaling In Neonatal Rats

Yan-Ping Xu,Jia-Jun Zhu,Fen Cheng,Ke-Wen Jiang,Wei-Zhong Gu,Zheng Shen,Yi-Dong Wu,Li Liang,Li-Zhong Du

DOI: https://doi.org/10.1530/JME-10-0143

2011-01-01

Journal of Molecular Endocrinology

Abstract:Effective treatment and/or prevention strategies for neonatal persistent pulmonary hypertension of the newborn (PPHN) have been an important topic in neonatal medicine. However, mechanisms of impaired pulmonary vascular structure in hypoxia-induced PPHN are poorly understood and consequently limit the development of effective treatment. In this study, we aimed to explore the molecular signaling cascades in the lungs of a PPHN animal model and used primary cultured rat pulmonary microvascular endothelial cells to analyze the physiological benefits of ghrelin during the pathogenesis of PPHN. Randomly selected newborn rats were exposed to hypoxia (10-12%) or room air and received daily s.c. injections of ghrelin (150 mu g/kg) or saline. After 2 weeks, pulmonary hemodynamics and morphometry were assessed in the rats. Compared with the control, hypoxia increased pulmonary arterial pressure, right ventricle (RV) hypertrophy, and arteriolar wall thickness. Ghrelin treatment reduced both the magnitude of PH and the RV/(left ventricle+septum (Sep)) weight ratio. Ghrelin protected neonatal rats from hypoxia-induced PH via the upregulation of phosphorylation of glycogen synthase kinase 3 beta (p-GSK3 beta)/beta-catenin signaling and associated with beta-catenin translocation to the nucleus in the presence of growth hormone secretagogue receptor-1a. Our findings suggest that s.c. administration of ghrelin improved PH and attenuated pulmonary vascular remodeling after PPHN. These beneficial effects may be mediated by the regulation of p-GSK3 beta/beta-catenin expression. We propose ghrelin as a novel potential therapeutic agent for PPHN.
Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Β/β-Catenin Signaling in Neonatal Rats.

Yan-ping Xu,Jiajun Zhu,Fen Cheng,Ke-wen Jiang,W. Gu,Zheng Shen,Yi-dong Wu,Li Liang,L. Du

DOI: https://doi.org/10.1530/jme-10-0143

2011-01-01

Journal of Molecular Endocrinology

Abstract:Effective treatment and/or prevention strategies for neonatal persistent pulmonary hypertension of the newborn (PPHN) have been an important topic in neonatal medicine. However, mechanisms of impaired pulmonary vascular structure in hypoxia-induced PPHN are poorly understood and consequently limit the development of effective treatment. In this study, we aimed to explore the molecular signaling cascades in the lungs of a PPHN animal model and used primary cultured rat pulmonary microvascular endothelial cells to analyze the physiological benefits of ghrelin during the pathogenesis of PPHN. Randomly selected newborn rats were exposed to hypoxia (10-12%) or room air and received daily s.c. injections of ghrelin (150 μg/kg) or saline. After 2 weeks, pulmonary hemodynamics and morphometry were assessed in the rats. Compared with the control, hypoxia increased pulmonary arterial pressure, right ventricle (RV) hypertrophy, and arteriolar wall thickness. Ghrelin treatment reduced both the magnitude of PH and the RV/(left ventricle+septum (Sep)) weight ratio. Ghrelin protected neonatal rats from hypoxia-induced PH via the upregulation of phosphorylation of glycogen synthase kinase 3β (p-GSK3β)/β-catenin signaling and associated with β-catenin translocation to the nucleus in the presence of growth hormone secretagogue receptor-1a. Our findings suggest that s.c. administration of ghrelin improved PH and attenuated pulmonary vascular remodeling after PPHN. These beneficial effects may be mediated by the regulation of p-GSK3β/β-catenin expression. We propose ghrelin as a novel potential therapeutic agent for PPHN.
Inhibition of Endoplasm Reticulum Stress by Ghrelin Protects Against Ischemia/reperfusion Injury in Rat Heart.

Gai-Gai Zhang,Xu Teng,Yue Liu,Yan Cai,Ye-Bo Zhou,Xiao-Hui Duan,Jun-Qiu Song,Yi Shi,Chao-Shu Tang,Xin-Hua Yin,Yong-Fen Qi

DOI: https://doi.org/10.1016/j.peptides.2009.03.024

IF: 3.867

2009-01-01

Peptides

Abstract:Ghrelin is a multi-functional polypeptide with cardiovascular protective effects. We aimed to explore whether the cardioprotective effect of ghrelin is mediated by inhibiting myocardial endoplasmic reticulum stress (ERS). A Langendorff model of isolated rat heart was used with ischemia/reperfusion (I/R; 40/120min). Cardiac function was monitored, and histomorphologic features, degree of myocardial injury, level of ERS markers, and number of apoptotic cardiomyocytes were determined. Compared with control group, the I/R group showed significantly decreased cardiac function, seriously damaged myocardial tissue, increased number of apoptotic cells, and overexpression of mRNA and protein of ERS markers. However, preadministration of ghrelin in vivo (10−8mol/kg, intraperitoneal injection, every 12h, twice in all) greatly ameliorated the damaged heart function, attenuated myocardial injury and apoptosis, and decreased the expression of ERS markers: it decreased the mRNA and protein levels of glucose-regulated protein78 (GRP78) and C/EBP homologous protein (CHOP), with reduced caspase-12 protein expression. Furthermore, in vitro, ghrelin directly inhibited the myocardial ERS response induced by tunicamycin or dithiothreitol in rat cardiac tissue. Ghrelin could protect the heart against I/R injury, at least in part, through inhibiting myocardial ERS.
Ghrelin and its biological effects on pigs.

Xiao-Ying Dong,Jian Xu,Sheng-Qiu Tang,Hai-Yun Li,Qing-Yan Jiang,Xiao-Ting Zou

DOI: https://doi.org/10.1016/j.peptides.2009.03.001

IF: 3.867

2009-01-01

Peptides

Abstract:Ghrelin is a 28 amino acid peptide, which produces its marked effects through binding to the endogenous ligand of the growth hormone secretagogue receptor (GHS-R). Based on the contemporary literatures, it was shown that ghrelin was involved in a series of biological functions including regulation of food intake, body weight, gastrointestinal (GI) motility, hormone secretion, glucose release, cardiovascular functions, enzyme release, cell proliferation and reproduction in pigs through binding to GHS-R 1a or unidentified receptors. It was also observed that ghrelin induced adipocyte and hepatocyte proliferation of primary cultured piglet. In this paper, recent research on ghrelin structure, distribution, GHS-R receptor, biological functions and its regulatory mechanisms for pigs are presented.
Ghrelin: integrative neuroendocrine peptide in health and disease

James T Wu,John G Kral

DOI: https://doi.org/10.1097/01.sla.0000118561.54919.61

Abstract:Objective: Ghrelin is a novel gastric hormone recognized in 1999 as a mediator of growth hormone release. Since growth hormone is anabolic, an important function of ghrelin may be to coordinate energy needs with the growth process. Newly discovered biologic roles of ghrelin imply that it may have other important physiological functions as well. This is a review of recent clinically relevant, yet less well-known, physiologic actions of ghrelin. Summary background data: Ghrelin has profound orexigenic, adipogenic, and somatotrophic properties, increasing food intake and body weight. Secreted predominantly from the stomach, ghrelin is the natural ligand for the growth hormone secretagogue receptor in the pituitary gland, thus fulfilling criteria of a brain-gut peptide. The brain-gut axis is the effector of anabolism by regulating growth, feeding, and metabolism via vagal afferents mediating ghrelin signaling. However, the wide tissue distribution of ghrelin suggests that it may have other functions as well. Methods: Systematic literature review of all PubMed citations between 1999 and August 2003 focusing on clinically relevant biochemical and physiological characteristics of ghrelin. Results: Ghrelin is an important component of an integrated regulatory system of growth and metabolism acting via the vagus nerve, and is implicated in a variety of altered energy states such as obesity, eating disorders, neoplasia, and cachexia. It also enhances immune responses and potentially down-regulates anti-inflammatory molecules. Ghrelin's role as a brain-gut peptide emphasizes the significance of afferent vagal fibers as a major pathway to the brain, serving the purpose of maintaining physiologic homeostasis. Conclusions: The discovery of ghrelin has increased our understanding of feeding regulation, nutritional homeostasis, and metabolic processes. Further characterization of ghrelin's functions will likely generate new pharmacological approaches to diagnose and treat different disease entities including those related to the over-nutrition of obesity and the catabolic response to surgical trauma.
Ghrelin Improves Disturbed Myocardial Energy Metabolism in Rats with Heart Failure Induced by Isoproterenol

Jian-Ping Xu,Hong-Xia Wang,Wen Wang,Li-Ke Zhang,Chao-Shu Tang

DOI: https://doi.org/10.1002/psc.1253

2010-01-01

Journal of Peptide Science

Abstract:To explore the effects of ghrelin on disturbed myocardial energy metabolism during chronic heart failure (CHF). Rats were subcutaneously injected with isoproterenol (ISO) for 10 days with or without ghrelin for another 10 days. Enzyme immunoassay was to measure ghrelin concentrations. Compared with the control group, ISO-treated rats showed suppressed cardiac function with high ghrelin/GHS-R expressions. These rats also showed the decreases in food consumption and weight. The decreased levels of plasma glucose and myocardial glucogen, but the high lactate in blood and myocardium showed myocardial metabolic disturbance. Compared with the group given ISO alone, the rats with ghrelin (20 and 100 mu g/kg/day) improved cardiac dysfunction and increased food intake by 13.5 and 14.2% (both P < 0.01), and rate of weight gain by 95% (P < 0.05) and 1.71-fold (P < 0.01), respectively. The plasma glucose were increased by 49.7 and 50.8% (both P < 0.01), and myocardial glucogen, by 40.5 and 51.7% (both P < 0.01), but blood lactate decreased by 1.56- and 1.96-fold (both P < 0.01), and myocardial lactate by 32.1 and 48.7% (both P < 0.05), respectively. Their MCT1 mRNA and protein expressions increased. The myocardial ghrelin/GHS-R pathway can be upregulated during CHF. The ghrelin can attenuate cardiac dysfunction and energy metabolic disturbance in CHF rats. Copyright (C) 2010 European Peptide Society and John Wiley & Sons, Ltd.
Ghrelin Reduces Rat Myocardial Calcification Induced by Nicotine and Vitamin D3 in Vivo.

Fei Wang,Tao Jiang,Chaoshu Tang,Zijie Su,Nong Zhang,Guizhong Li

DOI: https://doi.org/10.3892/ijmm.2011.710

IF: 5.314

2011-01-01

International Journal of Molecular Medicine

Abstract:Ghrelin, a newly discovered bioactive peptide, initially was identified as a strong stimulant for the release of growth hormone (GH) and that has improved cardiac function in patients suffering from end-stage chronic heart failure. Increasing evidence has demonstrated that ghrelin may have myocardial protective effects. However, the role of ghrelin in the pathogenesis of cardiovascular diseases remains unclear. In this study, an in vivo model of rat myocardial calcification induced by vitamin D3 and nicotine was used to study the possible mechanism in the regulatory action of ghrelin on the calcified myocardium. Calcification increased total Ca2+ content and 45Ca2+ deposition in the myocardium and alkaline phosphatase (ALP) activation in the plasma. Compared with the control group, ghrelin mRNA expression was up-regulated and the myocardium calcium content was significantly increased in vitamin D3 and nicotine-treated rats. Rats were subcutaneously injected with 1 or 10 nmol/kg ghrelin. Rats treated with both low- and high-dose ghrelin decreased total Ca2+ content and 45Ca2+ deposition in cardiac muscle and inhibited ALP activation in the myocardium and plasma, in a concentration-dependent manner. In addition, osteopontin (OPN) mRNA expression significantly decreased and that of endothelin (ET-1) significantly increased with myocardial calcification. Ghrelin treatment increased OPN expression at the mRNA level and reduced ET-1 mRNA expression in a dose-dependent manner. These results indicate that exogenous administration with ghrelin attenuates myocardial calcification induced by nicotine and vitamin D3, and that the possible mechanism is via the ghrelin-induced increase in the OPN mRNA levels and decrease in the ET-1 mRNA expression in the myocardium.
Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves.

Yuanjie Mao,Takeshi Tokudome,Kentaro Otani,Ichiro Kishimoto,Michio Nakanishi,Hiroshi Hosoda,Mikiya Miyazato,Kenji Kangawa

DOI: https://doi.org/10.1210/en.2012-1065

IF: 5.051

2012-01-01

Endocrinology

Abstract:Ghrelin is a GH-releasing peptide mainly excreted from the stomach. Ghrelin administration has been shown to inhibit cardiac sympathetic nerve activity (CSNA), reduce malignant arrhythmia, and improve prognosis after acute myocardial infarction (MI). We therefore investigated the effects and potential mechanisms of the action of endogenous ghrelin on survival rate and CSNA after MI by using ghrelin-knockout (KO) mice. MI was induced by left coronary artery ligation in 46 KO mice and 41 wild-type mice. On the first day, malignant arrhythmia-induced mortality was observed within 30 min of the ligation and had an incidence of 2.4% in wild-type and 17.4% in KO mice (P < 0.05). We next evaluated CSNA by spectral analysis of heart rate variability. CSNA, represented by the low frequency/high frequency ratio, was higher in KO mice at baseline (2.18 +/- 0.43 vs. 0.98 +/- 0.09; P < 0.05), and especially after MI (25.5 +/- 11.8 vs. 1.4 +/- 0.3; P < 0.05), than in wild-type mice. Ghrelin (150 mu g/kg, sc) 15 min before ligation suppressed the activation of CSNA and reduced mortality in KO mice. Further, this effect of ghrelin was inhibited by methylatropine bromide (1 mg/kg, ip) or by perineural treatment of both cervical vagal trunks with capsaicin (a specific afferent neurotoxin). Our data demonstrated that both exogenous and endogenous ghrelin suppressed CSNA, prevented the incidence of malignant arrhythmia, and improved the prognosis after acute MI. These effects are likely to be via the vagal afferent nerves. (Endocrinology 153: 3426-3434, 2012)
Viral and host strategies to take advantage of the innate immune response.

Yong Zhang,Michael E. Hinojosa,Noah Yoo,M. Holtzman

DOI: https://doi.org/10.1165/rcmb.2009-0213ED

IF: 7.748

2010-11-01

American Journal of Respiratory Cell and Molecular Biology

Abstract:The struggle between respiratory viruses and their hosts rages on. Any doubt of the importance of that battle is quickly quelled by the recent pandemic of swine flu attributable to H1N1-type influenza A virus (IAV), as well as the devastating outbreaks of avian flu (attributable to H5N1-type IAV) and severe acute respiratory syndrome (SARS) (attributable to SARS–corona virus). In addition to the viral influence on acute illness, we (and others) have presented a considerable amount of experimental evidence that respiratory viruses are responsible, at least in part, for the pathogenesis of chronic obstructive lung diseases such as asthma and chronic obstructive pulmonary disorder (1). In each instance, the severity of infection and the consequent impact of the virus on the host is likely dictated by the outcome of the chess game between the pathogen and the immune response. Thus, an understanding of the innate and adaptive immune responses to viruses (particularly respiratory viruses) remains an important public health issue, and one that can be addressed experimentally. In that regard, the article by Senft and colleagues in the April 2010 issue of the AJRCMB demonstrates once again how a common respiratory virus can resource its small genome to outwit the larger and more complex genomic repertoire of its human host (2). In particular, that report provides new evidence for how respiratory syncytial virus (RSV) can subvert the antiviral IFN signaling system in lung macrophages. The findings provide a timely opportunity to update in brief the critical roles of IFN signaling as well as cells of the innate immune system in the virus-versus-host struggle, and to describe how this information might translate into improvements in host defense and disease outcome.

Comparison of analysis techniques for the lattice Boltzmann method

Ghrelin and the cardiovascular system

Isolation in Portugal of West Nile virus from Anopheles maculipennis mosquitoes.

Ghrelin As a Treatment for Cardiovascular Diseases

The Treatment of Ghrelin on Cardiac Cachexia in Congestive Heart Failure

Effect of Ghrelin on Energy Metabolism in Chronic Heart Failure

Ghrelin Protects Heart Against ERS-induced Injury and Apoptosis by Activating AMP-activated Protein Kinase

Ghrelin inhibited pressure overload-induced cardiac hypertrophy by promoting autophagy via CaMKK/AMPK signaling pathway

Endogenous Ghrelin Attenuates Pressure Overload-Induced Cardiac Hypertrophy Via A Cholinergic Anti-Inflammatory Pathway

Recent Advances in the Biological Function of Ghrelin

Ghrelin and Blood Pressure Regulation

Protective Effects of Ghrelin on Ischemia/reperfusion Injury in the Isolated Rat Heart.

Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Beta/Beta-Catenin Signaling In Neonatal Rats

Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Β/β-Catenin Signaling in Neonatal Rats.

Inhibition of Endoplasm Reticulum Stress by Ghrelin Protects Against Ischemia/reperfusion Injury in Rat Heart.

Ghrelin and its biological effects on pigs.

Ghrelin: integrative neuroendocrine peptide in health and disease

Ghrelin Improves Disturbed Myocardial Energy Metabolism in Rats with Heart Failure Induced by Isoproterenol

Ghrelin Reduces Rat Myocardial Calcification Induced by Nicotine and Vitamin D3 in Vivo.

Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves.

Viral and host strategies to take advantage of the innate immune response.